Effects of Arginine Supplementation on Athletic Performance Based on Energy Metabolism: A Systematic Review and Meta-Analysis

Aitor Viribay 1, José Burgos 2, Julen Fernández-Landa 2, Jesús Seco-Calvo 3 and Juan Mielgo-Ayuso 4,*

1 Glut4Science, Physiology, Nutrition and Sport, 01004 Vitoria-Gasteiz, Spain; aitor@glut4science.com
2 Department of Nursing and Physiotherapy, University of León, 24071 León, Spain; joseburgos88@hotmail.com (J.B.); julenfdl@hotmail.com (J.F.-L.)
3 Institute of Biomedicine (IBIOMED), Physiotherapy Department, University of León, Researcher of Basque Country University, Campus de Vegazana, 24071 León, Spain; dr.seco.jesus@gmail.com
4 Department of Biochemistry Molecular Biology and Physiology, Faculty of Health Sciences, University of Valladolid, 42004 Soria, Spain

* Correspondence: juanfrancisco.mielgo@uva.es; Tel.: +34-975-129187

Received: 12 March 2020; Accepted: 24 April 2020; Published: 2 May 2020

Abstract: Nitric oxide related ergogenic aids such as arginine (Arg) have shown to impact positively on sport performance through several physiological and metabolic mechanisms. However, research results have shown to be controversial. The great differences regarding required metabolic pathways and physiological demands between aerobic and anaerobic sport disciplines could be the reasons. The aim of this systematic review and meta-analysis was to evaluate the effects of Arg supplementation on aerobic (≤VO₂max) and anaerobic (>VO₂max) performance. Likewise, to show the effective dose and timing of this supplementation. A structured search was carried out in accordance with PRISMA® (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement and PICOS guidelines in PubMed/MEDLINE, Web of Science (WOS), and Scopus databases from inception to January 2020. Eighteen studies were included which compare Arg supplementation with placebo in an identical situation and testing its effects on aerobic and anaerobic performance tests. Trials analyzing supplementation with other supplements were removed and there was not athlete’s level, gender, ethnicity, or age filters. The performed meta-analysis included 15 studies and random effects model and pooled standardized mean differences (SMD) were used according to Hedges’ g. Results revealed that Arg supplementation could improve aerobic (SMD, 0.84; 95% CI, 0.12 to 1.56; magnitude of SMD (MSMD), large; I², 89%; p = 0.02) and anaerobic (SMD, 0.24; 95% CI, 0.05 to 0.43; MSMD, small; I², 0%; p = 0.01) performance tests. In conclusion, acute Arg supplementation protocols to improve aerobic and anaerobic performance should be adjusted to 0.15 g/kg of body weight ingested between 60–90 min before. Moreover, chronic Arg supplementation should include 1.5–2 g/day for 4–7 weeks in order to improve aerobic performance, and 10–12 g/day for 8 weeks to enhance anaerobic performance.

Keywords: aminoacids; ergogenic aids; physical performance; nitric oxide; aerobic; anaerobic

1. Introduction

Athletes often turn to nutritional supplements in order to maintain health and maximize athletic performance [1]. Among them, proteins and amino acids represent the most consumed ergogenic aids, with a frequency of 35–40% [2]. However, the use of nutritional supplements with vasodilatory function are increasing considerably in the sport field, given that there is strong evidence that its intake...
has a positive effect on athletic performance [3–5]. In this sense, although nitrate and beetroot juice are the most studied vasodilatory supplements in this field [6,7], arginine (Arg) is an amino acid that has shown a vasodilator effect because it participates in the synthesis and bioavailability of nitric oxide (NO) [4,8]. For this reason, Arg supplementation has been used by athletes in order to obtain improvements in athletic performance [9–12].

Although Arg is a non-essential amino acid for adults because it is absorbed through dietary proteins [13] and synthesized in the small intestine from proline, glutamate, and glutamine [8,14], some research has shown that supplementation could be beneficial to increase athletic performance [15]. The most relevant benefit of Arg is related to NO synthesis and its role as a cell signaling molecule with physiological relevant effects [16]. NO has shown increased blood flow and improved muscle contraction, gas exchange, oxygen kinetics, and mitochondrial biogenesis [6,17]. Otherwise, Arg has also been shown to stimulate the release of growth hormone (GH) [18,19], which helps to promote cell growth and regulate the mobilization of fuels in the body that contributes to increase muscle mass and hypertrophy [20–22]. Moreover, Arg supplementation has presented a reduction of ammonia, lactate, fatty acids, and fat oxidation levels after exercise [23,24]. Likewise, Arg has shown an increase in glycerol post-exercise, with improved carbohydrate oxidation and oxygen efficiency [25,26], considering these potential benefits in endurance sport performance. Thus, Arg has displayed effects on different physiological and metabolic pathways that could improve athletic performance in both, endurance or “aerobic” and high intensity or “anaerobic” athletic performance [15].

Athletic performance in endurance sports, in which efforts commonly last 5 min or more and requires equal and/or less intensity than VO$_2$max, is related to the capacity of circulatory and respiratory systems to supply fuel and resynthesize adenosine triphosphate (ATP) by oxidative metabolism [27,28]. Therefore, endurance performance is determined by maximal oxygen uptake (VO$_2$max), ventilatory thresholds, and energy efficiency or economy [28,29]. In this sense, different Arg supplementation protocols (<7 days or acute) and dosages (6–10 g/day) have been shown to improve several physiological parameters and performance outcomes, such as time to exhaustion, mean power output, and exercise capacity in moderate-submaximal intensities [10,11,30]. These results could be explained only due to improvements in blood flow and oxygen supply to the muscles, because it seemed that longer supplementation periods are needed to enhance mitochondrial respiration and oxidative phosphorylation through NO pathway [6]. However, other studies did not show any improvement on total 5 km running time and on cycloergometer incremental test performance in experienced runners and recreationally active men, respectively [31,32].

On the other hand, performance in high intensities or anaerobic sports, requires greater intensity than VO$_2$max and depends on different metabolic pathways related to exercise duration [33]. In this sense, while high energetic phosphagen system (<6 s duration) is determinant for explosive disciplines, glycolysis represents the main energetic pathway for exercises between 1–5 min (with an increased contribution of oxidative phosphorylation proportionally with time), determined as high-intensity (~1 min) and intensive efforts (<5 min) [33–36]. Regarding anaerobic performance, chronic Arg supplementation (45–56 days) with low (2 g/day) and high (12 g/day) dosages could led to improve performance in one maximum repetition (1RM) bench press, Wingate test, and VO$_2$max intensity test [9,20]. These positive effects related with strength could be explained because of Arg enhance GH-releasing hormone, suppresses the endogenous GH-inhibiting hormone and increases insulin-like growth factor 1 (IGF-1) [37,38]. Moreover, Arg plays an essential role in the synthesis of Creatine, main substrate for phosphagen system and anaerobic performance [8]. However, other authors did not find any benefits on muscle strength, maximum number of repetitions, and sprint power after ingesting 6 g/day of Arg in both acute and chronic protocols [39–41].

Although Arg supplementation could be effective on aerobic and high-intensity sport disciplines performance mediated by several effects, current evidence is controversial and confusing. In this sense, there are a few systematic reviews that analyze the effects of Arg supplementation on different physiological and metabolic mechanisms in older adults and disease patients [42,43]. Moreover, a short
systematic review examined the connection between Arg and citrulline and sport performance [15]. However, to the best of the authors’ knowledge, there is not clearly and quantitatively analyzed information and distinction regarding the different involved effects in both aerobic and anaerobic performance capacities in the literature, and this may be necessary to better understand Arg supplementation reasons and protocols. Therefore, we proposed carrying out a systematic review and meta-analysis on the effects of Arg supplementation on exercise performance according to the main energy metabolism system used during exercise, with the main aim of analyzing current evidence and evaluating its impact on performance in both, aerobic and high-intensity or anaerobic, disciplines. In addition, this manuscript aims to show the effective doses and ideal moment of its intake.

2. Methods

2.1. Literature Search Strategies

This systematic review and meta-analysis was performed in accordance with PRISMA® (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement guidelines [44] and the PICOS model for the definition of the inclusion criteria: P (Population): “athletes”, I (Intervention): “impact of the Arg supplementation on sport performance”, C (Comparators): “same conditions with control or placebo”, O (Outcome): “sport performance”, and S (study design): “clinical trial” [45]. A systematic search of the scientific literature was performed to investigate the effects of Arg supplementation on sports performance. Studies were found by searching Web of Science (WOS), PubMed/MEDLINE, and Scopus from inception to 23rd January 2020, using the following Boolean search equation: “L-Arginine”[All Fields] OR “arginine”[All Fields] OR “AAKG”[All Fields] OR “arginine alpha-ketoglutarate”[All Fields] AND supplementation[All Fields] AND (“sports”[MeSH Terms] OR “sports”[All Fields] OR “sport”[All Fields]) OR (“exercise”[MeSH Terms] OR “exercise”[All Fields]) AND (“endurance”[All Fields] OR “performance”[All Fields] OR “aerobic”[All Fields] OR “anaerobic”[All Fields] OR “strength”[All Fields]). Over this search equation, other articles in this field were included by the snowball strategy. To identify duplicates and any potential missing studies, all titles and abstracts from the search were cross-referenced. The abstracts and titles were screened for a subsequent full-text review.

2.2. Inclusion and Exclusion Criteria

The inclusion criteria applied in this systematic review and meta-analysis to choice studies were (1) well-designed experiments that included Arg supplementation; (2) identical experimental condition in the placebo or control group; (3) testing the effects of Arg supplementation on sports performance; (4) clinical trial; (5) clear information concerning the Arg supplementation administration (timing and dosage); (6) published in any language; (7) clear information about funding sources; and (8) absence of conflict of interests. On the other hand, this exclusion criteria were used regarding the experimental procedures of the investigation: (1) Arg supplementation was mixed with other supplements or was a multi-ingredient compound; and (2) participants had a previous injury or health problems. There were no filters applied to the athletes’ athletic level, age, gender, or ethnicity to increase the analytic power of the analysis.

2.3. Study Selection

Two authors independently screened and agreed upon the selected studies for eligibility (A.V. and J.M.-A.). Likewise, after the inclusion/exclusion criteria were applied to each study, data on study source (including authors and year of publication), sample size, characteristics of the participants (level, race, and gender), supplement administration (dose and timing), and final outcomes of the interventions were extracted independently by two same authors (A.V and J.M.-A.) using a spreadsheet (Microsoft Inc, Seattle, WA, USA). Then, possible disagreements were resolved through discussion until a consensus was reached, or by third-party adjudication (J.F.-L.). In this sense, the Cohen’s kappa
coefficient, which indicate the intrater reliability, between authors was above 90 with a level of agreement “almost perfect” [46].

2.4. Outcome Measures

The literature was examined regarding the effects of Arg supplementation on sports performance using athletic performance outcome variables classified according to the duration of tests used. As 5 min test seems to be reliable in determining maximal aerobic velocity and therefore, how long a subject can maintain the lowest intensity at which VO₂max was achieved [47,48], authors established this criteria to arrange analyzed performance outcomes variables in ≤VO₂max and >VO₂max. Two studies met both criteria and, hence, were included in both performance analysis. Concretely, the outcomes obtained by Repeated Sprint Ability Test (RSAT), strength exercises as isokinetic flexion, isokinetic extension, and bench press, 1 min all out test, 1 km time trial (TT) and Wingate Test were included in >VO₂max. On the other hand, the outcomes obtained by Incremental test to exhaustion, 2 × 5 km TT, 60 min test at 80% of ventilatory threshold (VT), a 16.1 km TT and 2 × 6 min running followed by a running test until exhaustion. Harvard Step Test to measure VO₂max. capacity were included in ≤VO₂max. For the statistical analysis, the sample sizes, means and standard deviations of the different outcomes studied were extracted both in the group supplemented with Arg and in the control group and in the pre and post treatment. When there was no numerical data, it was requested to the authors or if the data were plotted as figures, the values were estimated based on the pixel count using images calibrated in ImageJ software (National Institutes of Health, Bethesda, MD, USA).

2.5. Publication Bias

Publication bias was assessed using Egger’s statistic test, where bias was deemed to be present at $p = < 0.05$ [49]. Corresponding funnel plots were created for visual interpretation, followed by an Egger’s statistic to confirm or refute publication bias (Figure 1). Egger’s analyses suggest that publication bias did not present finding in anaerobic performance ($z = 0.786; p = 0.432$). However, funnel plot showed publication bias in aerobic performance data ($z = 2.873; p < 0.05$).

![Figure 1. Funnel plot of standard error of anaerobic (a) and aerobic; (b) performance data by Hedges’ g. SE: standard error; SMD: standardized mean difference.](image)

2.6. Quality Assessment of the Experiments

In accordance with the Cochrane Collaboration Guidelines [50], methodological quality and risk of bias were evaluated by two authors independently (A.V. and J.M.-A.), and disagreements were resolved by discussion and/or third-party author (J.F.-L.). The interrater reliability (Cohen’s kappa) was 90 with a level of agreement “almost perfect” [46]. The list was separated in six different domains: selection bias (random sequence generation, allocation concealment); performance bias (blinding of participants and researchers); detection bias (blinding of outcome assessment); attrition bias (incomplete outcome data); reporting bias (selective reporting); and other types of bias. The domains were considered as...
‘low’ if criteria met a low risk of bias (probable bias unlikely to seriously alter the results) or ‘high’ if criteria presented a high risk of bias (probable bias that seriously weakens confidence in the results), or it was considered ‘unclear’ (plausible bias that raises some doubt about the results), if the risk of bias was unknown. Full details or each article and domains are presented in Figures 2 and 3.

|                                   | Random Sequence Generation (Selection Bias) | Allocation Concealment (Selection Bias) | Blinding of Participants and Personnel (Performance Bias) | Blinding of Outcome Assessment (Detection Bias) | Incomplete Outcome Data (Attrition Bias) | Selective Reporting (Reporting Bias) | Other Bias |
|-----------------------------------|--------------------------------------------|-----------------------------------------|----------------------------------------------------------|-------------------------------------------------|----------------------------------------|-------------------------------------|-----------|
| Abel et al., 2005                 | +                                          | ?                                       | +                                                        | +                                               | +                                     | +                                  | +         |
| Alvarees et al., 2012             | +                                          | ?                                       | +                                                        | +                                               | +                                     | +                                  | +         |
| Alvarees et al., 2014             | +                                          | ?                                       | +                                                        | +                                               | +                                     | +                                  | +         |
| Bailey et al., 2015               | +                                          | ?                                       | +                                                        | +                                               | +                                     | +                                  | +         |
| Birol et al., 2019                | +                                          | ?                                       | +                                                        | +                                               | +                                     | +                                  | +         |
| Camic et al., 2010                | +                                          | ?                                       | +                                                        | +                                               | +                                     | +                                  | +         |
| Campbell et al., 2006             | +                                          | ?                                       | +                                                        | +                                               | +                                     | +                                  | +         |
| Da silva et al., 2014             | +                                          | ?                                       | +                                                        | +                                               | +                                     | +                                  | +         |
| Forbes et al., 2013               | +                                          | ?                                       | +                                                        | +                                               | +                                     | +                                  | +         |
| Greer & Jones, 2011               | −                                          | −                                       | +                                                        | +                                               | +                                     | +                                  | +         |
| Hurst et al., 2014                | +                                          | ?                                       | +                                                        | +                                               | +                                     | +                                  | +         |
| Liu et al., 2009                  | +                                          | ?                                       | +                                                        | +                                               | +                                     | +                                  | +         |
| Meirelles & Matsuura, 2018        | −                                          | −                                       | +                                                        | +                                               | +                                     | +                                  | +         |
| Mor et al., 2018                  | +                                          | ?                                       | +                                                        | +                                               | +                                     | +                                  | +         |
| Olek et al., 2010                 | +                                          | ?                                       | +                                                        | +                                               | +                                     | +                                  | +         |
| Pahlavani et al., 2017            | +                                          | ?                                       | +                                                        | +                                               | +                                     | +                                  | +         |
| Vanhatalo et al., 2013            | +                                          | ?                                       | +                                                        | +                                               | +                                     | +                                  | +         |
| Yavuz et al., 2014                | +                                          | ?                                       | +                                                        | +                                               | +                                     | +                                  | +         |

**Figure 2.** Summary of risk of bias: authors’ judgements about each risk of bias item for all included studies.  
+ indicate low risk of bias;  
? indicate unknown risk of bias;  
+ indicate high risk of bias.
were performed in unrelated subjects, and 4 because of unsuitable outcomes. Thereby, a total of 18 pooled SD of changes scores were used to calculate variance. Random effects model was used based on DerSimonian and Laird method [52]. The Cohen criteria were followed to interpret the magnitude of SMD (MSMD): <0.2, trivial; 0.2–0.5, small; 0.5–0.8, moderate; and >0.8, large [53].

Statistic I² was calculated, as indicator of the percentage of observed total variation within studies due to real heterogeneity rather than chance, with the objective to avoid errors when using Q statistic in assessing heterogeneity [50]. I² values are included from 0 to 100%, representing a small amount of inconsistency between 25% and 50%, medium amount of heterogeneity between 50% and 75%, and a large amount of heterogeneity when I² value is higher than 75% [54]. In this sense, low, moderate, and high adjectives would be accepted referring to I² values of 25%, 50%, and 75%, respectively, although a restrictive categorization would not be adequate in all circumstances [54–56].

3. Results

3.1. Main Search

The literature search through electronic database identified a total of 120 records according to the selected search equation and 11 additional studies were included through reference list searches. However, only 18 studies met all the inclusion criteria (Figure 4). From these initial 131 articles, 16 were remove after duplication analysis. Out of remaining 115 studies, 57 were excluded: 17 were reviews and 40 were not related with humans. Thus, 58 articles were full-text assessed for eligibility. From them, 40 were removed with reasons: 21 included more than one supplement, 7 used other supplements, 8 were performed in unrelated subjects, and 4 because of unsuitable outcomes. Thereby, a total of 18 were included in the analysis for this systematic review. However, due to insufficient data for carrying out the meta-analysis, three studies [25,57,58] were removed from quantitative synthesis and, thereby, a total of 15 were included for analysis.
3.2. Arginine Supplementation

Table 1 displays that eight studies followed a randomized, double-blind, placebo-controlled design [9,11,12,20,31,59–61], seven randomized, double-blind, cross-over, placebo-controlled design [10,25,39,40,57,58,62] and three randomized, placebo-controlled design [32,41,63]. None of the included studies presented any conflict of interests. Out of 15, 6 studies were carried out in endurance or aerobically trained healthy athletes [11,25,31,40,59,61], 3 in team sport athletes (soccer) [9,41,60], 2 in combat sports athletes (judo and wrestlers) [10,58], 1 in resistance-trained males [20] and remaining 6 in healthy, recreationally active males and females [12,32,39,57,62,63]. Total study participants included in the systematic review were 394 (386 males and 8 females). Out of them, 282 were trained or elite athletes. Sixteen studies divided participants in placebo (PLA) or control (CON) group and Arginine (ARG) group [9,10,20,25,31,32,39–41,57–63]. The remaining two assigned participants in PLA or CON and two ARG groups [11,12], in order to compare different doses.

Supplementation was ingested by participants in both acute and chronic protocols (Table 1). Eleven studies carried out an acute Arg ingestion, between 30 min and 2 days before tests. Concretely, 5 used Arg supplementation 60 min before test [10,25,57,58,60], 2 studies 90 min before [11,62], 1 study [59] 80 min before, 1 study [39] 4 h and 30 min before test, another one [40] provided supplementation 60 min and 30 min before test, and a last one [63] 30 min previously. Remaining 7 studies used chronic
supplementation protocols between 7 and 45 days: in 3 of them, participants ingest Arg during 4 weeks or 28 days [12,31,61], while 1 study provided supplementation during 7 days [32]. Mor et al. [41] used a 14 days protocol, Pahlavani et al. [9] used a longer protocol of 45 days and Campbell et al. [20] during 8 weeks or 56 days.

In 14 studies, the Arg supplementation dose was absolute. Out of them, in 8 studies the protocol consisted of 6 g/day of Arg [31,32,40,41,58,59,62,63], in 2 trials 2 g/day was used [9,57], in 1 study 12 g/day was ingested [20], another one provided 3.7 g [39], Abel et al. [61] used 5.7 g/day and 2.85 g/day for each group and the remaining one provided 1.5 g/day and 3 g/day [12]. Relative supplementation dose was used in 3 studies: 0.075 g·kg⁻¹ body mass [25] and 0.15 g·kg⁻¹ body mass [10,60]. The exception was the trial carried out by Hurst et al. [11], in which both, absolute (6 g/d) and relative (0.15 g·kg⁻¹ body mass), were provided to participants.

Table 1. Participant and intervention characteristics of the studies included in the systematic review and meta-analysis

| General Characteristic | Intervention Characteristic | Studies Included |
|------------------------|-----------------------------|------------------|
| Study Design           | Randomized, double-blind and placebo-controlled | 8 studies [9,11,12,20,31,59–61] |
|                        | Randomized, double-blind, cross-over and placebo-controlled | 7 studies [10,25,39,40,57,58,62] |
|                        | Randomized and placebo-controlled | 3 studies [32,41,63] |
| Conflict of Interests  | None | 18 studies [9–12,20,25,31,32,39–41,57–63] |
| Subjects Characteristics| Endurance-trained | 6 studies [11,25,31,59,61] |
|                        | Fight sports athletes | Judo—1 study [58] |
|                        | Wrestlers | 1 study [10] |
|                        | Soccer athletes | 3 studies [9,41,60] |
|                        | Resistance-trained | 1 study [20] |
|                        | Active | 6 studies [12,32,39,57,62,63] |
| Type of Arginine       | L-Arginine | 15 studies [9–12,25,31,32,40,41,57–60,62,63] |
|                        | Arginine Aspartate | 1 study [61] |
|                        | Arginine Alpha-Ketoglutarate | 2 studies [20,39] |
| Type of Arginine       | Absolute | 14 studies [9,12,20,31,32,39–41,57–61,63] |
| Administration         | Based on individual’s body mass | 3 studies [3,10,13] |
|                        | Both | 1 study [4] |
| Dose Used              | 12 g/day | 1 study [20] |
|                        | 6 g/day | 8 studies [31,32,40,41,58,59,62,63] |
|                        | 3.7 g/day | 1 study [39] |
|                        | 2 g/day | 2 studies [9,57] |
|                        | 5.7 d/day (group 1) and 2.85 g/day (group 2) | 1 study [61] |
|                        | 1.5 d/day (group 1) and 3 g/day (group 2) | 1 study [12] |
|                        | 0.075 g·kg⁻¹ body mass | 1 study [25] |
|                        | 0.15 g·kg⁻¹ body mass | 2 studies [10,60] |
|                        | 6 g/day (group 1) and 0.15 g·kg⁻¹ body mass (group 2) | 1 study [11] |
Table 1. Cont.

| General Characteristic | Intervention Characteristic | Studies Included |
|------------------------|-----------------------------|------------------|
| Acute                  | 60 min before test          | 5 studies [10,25,57,58,60] |
|                        | 90 min before test          | 2 studies [11,62] |
|                        | 80 min before test          | 1 study [59] |
|                        | 4 h + 30 min before test    | 1 study [39] |
|                        | 60 min + 30 min before test | 1 study [40] |
|                        | 30 min before test          | 1 study [63] |
| Chronic                | 56 days or 8 weeks          | 1 study [20] |
|                        | 45 days                     | 1 study [9] |
|                        | 28 days or 4 weeks          | 3 studies [12,31,61] |
|                        | 14 days                     | 1 study [41] |
|                        | 7 days                      | 1 study [32] |

3.3. Effect of Arginine on Anaerobic Performance (>VO₂max)

Table 2 presents the different tests carried out in selected studies determining performance above VO₂max intensity and measured outcomes. RSAT was used in 2 studies [41,60]. Strength exercises as isokinetic flexion, isokinetic extension, and bench press were used in other 2 studies [40,59], 1 min all-out test was carried out by Bailey et al. [32], 1 km TT by Hurst et al. [11], and Wingate Test in Olek et al. [57] and Campbell et al. [20] trials.

The supplementation of Arg showed improvements in Wingate Test and Upper Body 1RM [20] and in chin-ups total repetitions [39] but the remaining 8 trials did not find any differences in treatment [11,32,40,41,57–60].
Table 2. Summary of the studies included in the systematic review that investigated the effect of L-Arginine on VO2max Performance (test lasting less than 5 min).

| Author(s)       | Population                                                                 | Intervention                                                                 | Test                                                                 | Outcomes                                                                 | Main Conclusion   |
|-----------------|----------------------------------------------------------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------|--------------------------------------------------------------------------|-------------------|
| Alvares, T.S. et al., 2012 | 15 healthy male volunteers with previous resistance training experience. Arg group 26.3 ± 4.9 years vs. PLA 24.7 ± 1.8 years. | Randomized, double-blind, placebo-controlled. 6 g of L-Arg (80 min before test). | Dominant elbow flexion and extension exercise with an isokinetic dynamometer. 3 sets of 10 maximal voluntary contractions. | • Peak Torque  ↔  • Total Work ↔ | ↔ |
| Bailey S.J., et al., 2015 | 10 healthy, recreationally active men (19 ± 1 years). | Randomized, double-blind, placebo-controlled. 6 g/d of L-Arg (7 days). | Day 6: 1 min all out cycle sprint. | • Peak Power ↔ • Total Work ↔ | ↔ |
| Birol A. et al., 2019 | 20 volunteer healthy male football players (18.30 ± 0.48 years). | Randomized, double-blind, placebo-controlled. L-Arg 0.15 g/kg/day (60 min before test). | RSAT: 12 × 20 m with 30 s rest. | • Total sprint time ↔ | ↔ |
| Campbell B., et al., 2006 | 35 resistance-trained adult men (39.8 ± 5.8 years). | Randomized, double-blind, placebo-controlled. 12 g/d (4 g × 3) Arg Alpha-Ketoglutarate (8 weeks). | Upper body flat bench 1RM, Wingate test Isokinetic leg extension 50 rep. | • Upper body 1RM ↑ • Peak power ↑ • Time to Peak power ↑ • Rate to Fatigue ↑ • Isokinetic leg extension ↔ | ↑ |
| Greer B.K. et al., 2011. | 12 trained college-aged men (22.6 ± 3.9 years). | Randomized, double-blind, placebo-controlled, cross-over. 3.7 g Arg Alpha-Ketoglutarate (4 h + 30 min pre-test). | 3 sets of chin-ups, reverse chin-ups and push-ups to exhaustion. | • Chin-ups ↑ • Reverse Chin-ups ↔ • Push-ups ↔ | ↑ |
| Hurst H.T., et al., 2014. | 8 healthy, trained male cyclists (21.00 ± 1.41 years). | Randomized, double-blind, placebo-controlled. Group 1: 6 g L-Arg, Group 2: 0.15 g·kg⁻¹ body mass (90 min before test). | 1 km TT in cycloergometer. | • Time to complete Group 1 ↔ • Power output Group 1 ↔ • Time to complete Group 2 ↔ • Power output Group 2 ↔ | ↔ |
| Liu T.H., et al., 2009. | 10 elite male college judo athletes (20.2 ± 0.6 years). | Randomized, cross-over, placebo-controlled. 6 g/d L-Arg (2 days, 60 min before test). | 13 × All out test: 20 s with 15 s rest. | • Total power ↔ | ↔ |
| Menelles C.M., et al., 2018 | 12 healthy university students, resistance trained males. (27 ± 3 years). | Randomized, double-blind, cross-over, placebo-controlled. 6 g L-Arg (3 g × 3) before test + 3 g 30 min before test. | Bench press in a Smith Machine and unilateral knee extension of the right leg. | • Bench press repetitions ↔ • Knee extension repetitions ↔ | ↔ |
| Mor A., et al., 2018 | 28 amateur male soccer players (18–30 years). | Randomized, placebo-controlled. 6 g/d L-Arg (14 days). | Running Anaerobic Sprint Test (RAST): 6 × 32 m with 10 s rest. | • Mean power ↔ | ↔ |
| Olek R.A., et al., 2010. | 6 healthy, active, but not highly trained volunteers (23.2 ± 0.5 year). | Randomized, double-blind, cross-over, placebo-controlled. 2 g L-Arg (60 min before test). | 3 × All out 30 s Wingate Tet in Cycloergometer with 4 min rest. | • Power output ↔ | ↔ |

↑: statistically higher effects; ↓: statistically lower effects. ↔ No effect. 1RM: one maximum repetition; Arg: Arginine; PLA: Placebo; RSAT: Repeated Sprint Ability Test.
3.4. Effect of Arginine on Aerobic Performance ($\leq$VO$_2$max)

Table 3 shows the tests, measured outcomes and effects of Arg supplementation on aerobic or $\leq$VO$_2$max performance. Out of 11 studies, 6 tested performance with a cycloergometer [10–12,25,32,61], 4 in running protocols [20,31,62,63], and 1 remaining step protocol [9]. Incremental test to exhaustion was used in 5 trials [10,12,20,32,61] and 2 × 5 km TT in 2 other studies [31,63]. Forbes et al. [25] carried out a 60 min test at 80% of VT, Hurst et al. [11] a 16.1 km TT and Vanhatalo et al. [62] 2 × 6 min running followed by a running test until exhaustion. Lastly, Pahlavani et al. [9] used Harvard Step Test to measure VO$_2$max capacity.

Improvements in performance were found in four studies, corresponding to reduced time to exhaustion [10], increased power output in one of the two ARG group [11], physical working capacity [12] and performance score [9]. In the remaining trials [11,20,25,32,59,61–63], treatment did not show any performance improvements.
Table 3. Summary of the studies included in the systematic review that investigated the effect of L-Arginine on ≤VO₂max performance (test lasting 5 min or more).

| Author(s) | Population | Intervention | Test | Outcomes | Main Conclusion |
|-----------|------------|--------------|------|----------|----------------|
| Abel, T. et al., 2005 | 30 male endurance-trained athletes (Group 1: 38.5 ± 10 years; Group 2: 34.4 ± 8.6 years) | Randomized, double-blind, placebo-controlled. Group 1: 5.7 g/d Arg-Aspartate; Group 2: 2.85 g/d Arg-Aspartate. (4 weeks). | Incremental cycloergometer test | Time to exhaustion Group 1 ↔ Time to exhaustion Group 2 | ↔ |
| Alvares, T.S. et al., 2014 | 15 healthy experienced runners (11 males and 4 females) (36.8 ± 7.1 years). | Randomized, double-blind, placebo-controlled. 6 g/d of encapsulated L-Arg hydrochloride (4 weeks). | 2 x 5 Km TT running with 10 min recovery | Total running time. | ↔ |
| Bailey S.J., et al., 2015 | 10 healthy, recreationally active men (19 ± 1 years). | Randomized, double-blind, placebo-controlled. 6 g/d of L-Arg (7 days). | Day 7: Time to exhaustion test in cycloergometer | Time to exhaustion. | ↔ |
| Camic, C.L. et al., 2010 | 50 college-aged men (23.9 ± 3.0 years). | Randomized, double-blind, placebo-controlled. 3 groups: (a) placebo (n = 19); (b) 1.5 g/d Arg (n = 14); or (c) 3.0 g/d Arg (n = 17) (4 weeks). | Incremental test to exhaustion in cycloergometer | PWC_FT Group 1 ↑ PWC_FT Group 2 ↑ | ↑ |
| Campbell B., et al., 2006 | 35 resistance-trained adult men (59.8 ± 5.8 years). | Randomized, double-blind, placebo-controlled. 12 g/d (4 g × 3) Arg Alpha-Ketoglutarate (8 weeks). | Bruce protocol: Incremental test running | Time to exhaustion | ↔ |
| Da Silva D.V., 2014 | 15 physically active and healthy volunteers (11 males and 4 females). Arg group: 36.8 ± 7.1 years; PLA: 30.6 ± 9.5 years). | Randomized, placebo-controlled. 6 g/d of L-Arg (30 min before test). | 2 x 5 km TT running with 10 min recovery | Total running time. | ↔ |
| Forbes S.C., et al., 2013 | 15 aerobically trained men (age: 28 ± 5 years). | Randomized, double-blind, placebo-controlled, cross-over. L-Arg 0.075 g·kg⁻¹·body mass (60 min before test). | 60 min at 80% of VT incycloergometer | Average power output at ventilatory threshold. | ↔ |
| Hurst H.T., et al., 2014 | 8 healthy, trained male cyclists (21.00 ± 1.41 years). | Randomized, double-blind, placebo-controlled. Group 1: 6 g L-Arg, Group 2: 0.15 g·kg⁻¹·body mass (90 min before test). | 16.1 km TT in cycloergometer | Time to complete Group 1 ↔ Power output Group 1 ↔ Time to complete Group 2 ↔ Power output Group 2 ↑ | ↔ |
| Pahlavani N., et al., 2017 | 56 male soccer players (20.85 ± 4.29 years). | Randomized, double-blind, placebo-controlled. 2 g/d L-Arg (45 days). | Harvard Step Test | Performance Score | ↑ |
| Vanhatalo A., et al., 2013 | 18 healthy, recreationally active male students (22 ± 3 years). | Randomized, double-blind, cross-over placebo-controlled. 6 g/d of L-Arg (90 min before test). | 2 x 6 min running moderate test + 1 x running test until exhaustion | Time to exhaustion | ↔ |
| Yavuz, H.U., et al., 2014 | 9 volunteer elite male wrestlers (24.7 ± 3.8 years). | Randomized, placebo-controlled, cross-over. L-Arg 0.15 g·kg⁻¹·body mass (60 min before test). | Incremental test to exhaustion in cycloergometer | Time to exhaustion | ↑ |

↑: statistically higher effects; ↓: statistically lower effects. ↔ No effect. Arg: Arginine; PLA: Placebo; TT: Total Time trial; PWCFT: Physical working capacity at the fatigue threshold; VT: ventilatory threshold.
3.5. Effect on Anaerobic Performance (>VO\textsubscript{2}\text{max}) Meta-Analysis

Figure 5 shows that Arg presented small and significant effect on anaerobic performance (Hedges’ g (SMD) = 0.24; 95% CI (0.05–0.43); \( p = 0.01 \)). The meta-analysis reported small amount of inconsistency between studies reviewed (I\(^2\) = 0%; \( p = 0.85 \)). Three analyzed studies presented positive effects on anaerobic performance outcomes after Arg supplementation. Among them, Campbell et al. [20] obtained strong improvements in upper body 1RM and in Wingate Test parameters like peak power, time to peak power and rate of fatigue. On the other hand, Hurst et al. [11] showed small and not significantly positive effects on time to completion and power output during 1 km TT in cycloergometer, as well as Birol et al. [60] regarding total sprint time during RSAT. Although these results were not significant, clear Arg favorable tendencies were shown in original trials. In this sense, due to statistical circumstances, such as low participants number and followed criteria, results could not be considered as statistically significant (\( p < 0.05 \)) in each study. However, in our meta-analysis, once all studies were analyzed, significantly positive results were obtained in favor of Arg supplementation, showing that, on the whole, Arg effects regarding anaerobic outcomes were favorable (\( p = 0.01 \)).

| Study or Subgroup | Weight | Std. Mean Difference IV, Random, 95% CI | Std. Mean Difference IV, Random, 95% CI |
|-------------------|--------|----------------------------------------|----------------------------------------|
| Arales 2012       | 3.5%   | -0.04 [-1.02, 0.93]                    |                                         |
| Arales 2012       | 3.5%   | -0.10 [-1.12, 0.91]                    |                                         |
| Bailey 2015       | 4.7%   | 0.02 [-0.66, 0.90]                     |                                         |
| Bailey 2015       | 4.7%   | 0.00 [-0.88, 0.88]                     |                                         |
| Birol 2019        | 4.0%   | 0.00 [-0.10, 1.09]                     |                                         |
| Campbell 2006     | 7.6%   | 0.68 [-0.03, 1.68]                     |                                         |
| Campbell 2008     | 7.6%   | 0.74 [-0.04, 1.43]                     |                                         |
| Campbell 2006     | 7.6%   | 0.51 [-0.17, 1.19]                     |                                         |
| Campbell 2006     | 7.6%   | 0.00 [-0.67, 0.67]                     |                                         |
| Greer 2011        | 5.6%   | -0.10 [-0.90, 0.70]                    |                                         |
| Greer 2011        | 5.6%   | -0.04 [-0.64, 0.76]                    |                                         |
| Greer 2011        | 5.6%   | 0.00 [-0.60, 0.90]                     |                                         |
| Hurst 2014        | 3.5%   | 0.67 [-0.35, 1.68]                     |                                         |
| Hurst 2014        | 3.5%   | 0.85 [-0.19, 1.89]                     |                                         |
| Hurst 2014        | 3.5%   | 0.72 [-0.26, 1.68]                     |                                         |
| Hurst 2014        | 3.5%   | 0.00 [-0.70, 0.70]                     |                                         |
| Meireles 2010     | 5.6%   | -0.07 [-0.73, 0.57]                    |                                         |
| Meireles 2010     | 5.6%   | 0.09 [-0.70, 0.40]                     |                                         |
| Mor 2018          | 6.6%   | -0.01 [-0.75, 0.73]                    |                                         |

Total (95% CI) = 100.0% 0.24 [0.05, 0.43].

| Heterogeneity: Tau\(^2\) = 0.00; Chi\(^2\) = 11.66, df = 18 (\( P = 0.85 \)); \( p = 0.85 \). |
| Test for overall effect: Z = 2.50 (\( P = 0.01 \)). |

Figure 5. Forest plot comparing the effects of arginine supplementation on anaerobic (>VO\textsubscript{2}\text{max}) performance.

3.6. Effect on Aerobic Performance (≤VO\textsubscript{2}\text{max}) Meta-Analysis

Arg showed large and significant effect on aerobic performance (Hedges’ g (SMD) = 0.84; 95% CI (0.12–1.56); \( p = 0.02 \)) (Figure 6). The meta-analysis reported a large heterogeneity between the studies reviewed (I\(^2\) = 89%; \( p < 0.001 \)). Regarding the effects, Camic et al. [12] and Pahlavani et al. [9] showed large improvements in favor of Arg supplementation in physical working capacity at the fatigue threshold, and in the Harvard Step Test performance score, respectively. Moderate positive results were obtained by Yavuz et al. [10] during a cycloergometer incremental test to exhaustion. Similarly, Hurst et al. [11] showed moderate improvements in power output during 16.1 km TT in cycloergometer. However, these results were only observed in one of the two groups analyzed, with no small significant positive results in time to completion for group 1 and 2, and power output for group 1.
with strong evidence [4,5]. In this line, although 6 g/day Arg supplementation ingested between 60–90 min before exercise (acute protocol) have shown to improve on anaerobic and aerobic performance outcomes. In addition, 1.5–2 g/day Arg supplementation for 4–7 weeks (chronic protocol) and longer doses (10–12 g/day for 8 weeks) may also be beneficial to enhance aerobic and anaerobic performance, respectively.

Regarding dosage, differences are observed between acute and chronic protocols, suggesting that both strategies could have different mechanisms and responses. In that line, 0.15 g/kg body mass (≈10–11 g) of Arg supplementation ingested between 60–90 min before exercise (acute protocol) have shown to improve on anaerobic and aerobic performance outcomes. In addition, 1.5–2 g/day Arg supplementation for 4–7 weeks (chronic protocol) and longer doses (10–12 g/day for 8 weeks) may also be beneficial to enhance aerobic and anaerobic performance, respectively.

Regarding the well-known role of Arg related with NO production and increased blood flow and vasodilation, it has been suggested to favorably impact on training adaptations [64]. However, there are few studies analyzing these effects. In fact, due to the limited and controversial results about Arg supplementation on performance variables, Arg supplementation is not included as an ergogenic aid with strong evidence [4,5]. In this line, although 6 g/day seems to be the most used protocol, there are no clear timing and dose protocols related with sport performance. While, results obtained in this systematic review and meta-analysis indicated that an Arg supplementation with 6 g/day did not have significative effects on aerobic and anaerobic performance outcomes, higher doses (≥10 g) seem to be more effective on both anaerobic and aerobic performance outcomes. In this sense, these results depend on the timing of Arg ingestion. Given that nitrate and nitrite blood levels are increased 2.5–3 h after nitrate-rich supplement intake [65], and Arg pharmacokinetic tests have shown a maximum plasma concentration between 30–90 min after ingestion [66], acute ingestion protocols of Arg and other supplements related with NO metabolism have been analyzed in several studies. However, chronic supplementation protocols seem to be necessary to obtain major adaptations in other NO supplements as beetroot juice or nitrate [6]. Present work suggests that when acute protocols are used, higher doses (≥10 g) are needed to show improvements on aerobic performance, while when chronic ingestion protocols are followed, lower doses (1.5–3 g/day) may be enough to show benefits. Therefore, it suggests that studying differences between acute and chronic supplementation protocols could be essential to understand what dosage is more adequate in order to obtain performance optimization.

The physiological and metabolic differences between aerobic and high-intensity sport disciplines are relevant [33]. While anaerobic performance depends on the capacity to rapidly synthesize ATP mainly via phosphagen system or cytosolic glycolysis (overreaching the capacity to oxidize lactate),
performance in aerobic sports like road cycling or endurance running is determined by the capacity to oxidize lactate and supply ATP demands via oxidative phosphorylation [28,35,36]. In this line, nutrition and supplementation represents an important tool to optimize sport performance, especially in aerobic disciplines [5,67]. Given that NO pathway is involved in some beneficial physiological aerobic mechanisms, such as improved economy, gross efficiency, ventilatory kinetics, and metabolic responses, trying to optimize them with supplementation could be an adequate strategy [68]. Arg plays an essential role on endogenous NO synthesis and, thus, on some major physiological responses. Therefore, Arg supplementation could lead to improve training and competing performance due to the higher capacity to maintain work while prolonged exercising [9,10,12]. Because of that, Arg supplementation could be recommended for the improvement of anaerobic and aerobic sport disciplines performances.

4.1. Effect on Anaerobic Performance (>VO₂max)

Explosive (6 s), high-intensity (<1 min) and intensive (<5 min) efforts are determined by the anaerobic power and capacity, but there are some differences on metabolic and physiological demands between them [33,35]. From metabolic point of view, the main fuel substrates to rapidly synthesize ATP in anaerobic exercise is phosphocreatine and lactate. Therefore, intramuscular creatine content, glycolytic power, and buffer capacity are determinant factors [35,36]. On the other hand, physiologically, neuromuscular mechanisms, muscle contraction function, and structural factors such as muscle fiber composition (type II) are essential to ensure high intensity performance [36]. In this line, NO-pathway related supplements have shown, among other effects, to have specific impact on type II fibers improving anaerobic performance [69]. Moreover, Arg supplementation may have direct effects improving creatine resynthesis and reducing lactate accumulation [23,38].

Regarding anaerobic performance, the most commonly used measurement tests are Wingate test, short time trials (1–2 km), isokinetic exercises, 1RM and, in team sports, the RSAT [70–72]. In this sense, high doses (12 g/d) of chronic Arg supplementation (8 weeks) led to significant improvements in Wingate test parameters (peak power, time to peak power, and rate of fatigue), as well as enhanced 1RM performance in well resistance-trained subjects [20]. However, although they did not observe significant effects on RSAT total sprint time [60] and time to complete and average power output during a 1 km TT [11], high doses of Arg (0.15 g/kg ≈ 10–11 g) ingested 60–90 min before exercise led to a clear improvement tendency in these anaerobic parameters. In the same line, 2–6 g/d of acute Arg supplementation (60–90 min before exercise) did not show significant performance improvements in Wingate Test, 20” all out sprint and 1 km TT, although tendency in this last trial was also positive [11,57,58]. Likewise, 6 g/d for 7–14 days did not show any significant improvements in 1 min all out cycling sprint in recreationally active men [32] and in anaerobic sprint capacity (6 consecutive sprints) in soccer players [41]. Moreover, 3.7–6 g/d of Arg supplementation did not display significant beneficial effects regarding acute (30–80 min) or chronic (8 weeks) protocols on strength performance and sprinting capacity. Although it could be reasonable to expect greater anaerobic improvements with Arg supplementation due to enhanced blood flow and reduced lactate accumulation, among other mechanisms, positive results obtained in trials showed small significant effects but these had a tendency that was clear in some of analyzed trials. However, when global analysis was made, it showed that these improvements were represented with a higher and significant statistical power.

Therefore, these results suggest that regardless of fitness level and timing of supplementation, lower dosages are insufficient to improve high intensity anaerobic performance and that higher doses could be needed in both acute and chronic protocols. Regarding this, a supplementation of 0.15 g/kg body weight taken 60–90 min before exercise (acute protocol) or 10–12 g Arg supplementation for 8 weeks (chronic protocol) could led to improvements on anaerobic performance.

4.2. Effect on Aerobic Performance (≤VO₂max)

Aerobic performance requires a great metabolic flexibility and a great cardiovascular capacity that supplies oxygen needs during prolonged exercise [28,73]. Although genetic predisposition represents an
important requirement to perform in aerobic disciplines, looking for training and nutrition protocols to improve performance in such demanding disciplines is essential [74]. Beyond nutritional and hydration aids like carbohydrate-rich foods and electrolyte drinks, ergogenic aids such as caffeine or vasodilatory aids are often used [1,3]. In this regard, 1.5–3 g/d of chronic Arg supplementation (4–7 weeks) improved physical working capacity at the fatigue threshold in amateur and healthy-untrained subjects [9,12], showing lower fatigue related metabolites concentration such as ammonia and lactate, as well as a higher muscular power, endurance, and blood flow. On the other hand, a range of 2.85–5.7 g/d Arg supplementation for 4–8 weeks did not show statistical effects on time to exhaustion in running and cycling in endurance well-trained athletes [31,61]. Even higher dosage of 12 g/d Arg supplementation during more prolonged duration (8 weeks), did not present any improvements on time to exhaustion while running an incremental test protocol in resistance trained athletes [20]. These controversial results could be explained attending to subjects physical fitness, considering that Arg supplementation could have lower positive effects in well-trained subjects comparing with untrained ones as documented in other vasodilatory supplements [75].

Regarding acute supplementation, 0.15 g/kg (≈10–11 g) of Arg ingested between 60–90 min before exercise, led to improve time to exhaustion and power output in cycling endurance test in both trained and untrained subjects [10,11]. These effects could be explained due to reduced VO$_2$ slow components, anaerobic reserves use, reduced metabolites of fatigue, and ATP cost of muscle force production [10,11]. However, Arg supplementation within 5.7–6 g between 30–90 min previous to exercise, seemed not to show beneficial effects on total running time and average power output at ventilatory threshold in both endurance-trained and recreationally active subjects [11,25,62,63]. These differences suggest that when it comes to improving the physiological and metabolic responses related with enhanced aerobic performance, acute Ag supplementation protocols with higher doses (≈10–11 g absolute or 0.15 g/kg), independently of fitness status, should be followed.

Chronic and acute supplementation protocols could have different physiological mechanisms of action and these may be closely and directly related with different Arg dosages. In this regard, results obtained in this systematic review and meta-analysis demonstrated that aerobic performance could be optimized when Arg supplementation is followed in both acute (higher dosage) and chronic (lower dosage) protocols. However, these effects have to be taken with caution due to the publication bias found in the included aerobic performance included studies. Finally, considering that different physiological responses are documented on trained and untrained athletes when other NO-related supplement (beetroot juice) is ingested [6], it suggests that Arg supplementation dosages may need to be adjusted according to the subjects fitness level.

4.3. Strength, Limitations, and Future Lines of Research

The few total number of studies (n = 18) carried out in this systematic review and meta-analysis related to Arg supplementation could represent a limitation. On the other hand, the exhaustive methodology followed by authors in both systematic review and meta-analysis, concerning studies selection and outcomes analysis, interpretation, and quantification represents also a strong point. In fact, when assessing the review and meta-analysis quality by AMSTAR guidelines, the score obtained was ‘high quality’ [76]. In the same line, this meta-analysis was carried out with a strong statistical power and confidence, which constitute an important point in favor. Regarding supplementation, all included studies use only Arg with no other supplements, compared with a placebo, what limits the possibility to obtain synergistic or antagonistic effects along with other compounds. Moreover, there are some other limitations regarding supplementation protocols, doses and timing. Due to controversial results around Arg supplementation and its effects in the current literature [5], adequate dosages and supplementation duration are not yet well established. Because of that, there were found out some different and heterogeneous supplementation and timing protocols that limited the extraction of strong conclusions. In addition, performance outcomes and protocols used in studies were dissimilar and, beyond their classification into anaerobic and aerobic performance, differences were found within
each section regarding mainly used metabolic pathways. In the same line, the heterogeneity and the publications bias obtained in aerobic performance studies, mean that practitioners should take these results with caution when applying the analyzed outcomes to reality.

Future lines of research should focus on homogenizing Arg supplementations protocols regarding dosages and timing, due to the current miscellaneous methods. To our understanding, and taking into account the results obtained, new Arg dosages should be proposed in favor of higher and chronic supplementation protocols, as well as studying the differences between elite and amateur subjects. Finally, a novel research line should be considered studying the Arg absorption capacity and involved mechanisms in athletes, as this could represent a crucial understanding of supplementation knowledge.

5. Conclusions

This systematic review and meta-analysis have shown that Arg supplementation could have positive effects on anaerobic and aerobic performance related physical test outcomes. The effective dose of Arg supplementation in acute protocols should be adjusted to 0.15 g/kg (≈10–11 g) ingested between 60–90 min before exercise for improve both aerobic and anaerobic disciplines. On the other hand, chronic Arg supplementation of 1.5–2 g/day for 4–7 or longer doses (10–12 g/day for 8 weeks) presented a positive impact on aerobic and anaerobic performance, respectively.

Author Contributions: A.V. and J.M.-A.: Conception and design, analysis and interpretation of the data, drafting of the paper, and critical review and approval of the final version submitted for publication. J.B. and J.F.-L.: Analysis and interpretation of the data, drafting of the paper, and critical review and approval of the final version submitted for publication. J.S.-C.: Drafting of the paper and critical review and approval of the final version submitted for publication. All authors have read and agreed to the published version of the manuscript.

Funding: The authors declare no funding sources.

Conflicts of Interest: The authors declare no conflict of interests.

References

1. Garthe, I.; Maughan, R.J. Athletes and Supplements: Prevalence and Perspectives. Int. J. Sport Nutr. Exerc. Metab. 2018, 28, 126–138. [CrossRef]
2. Baltazar-Martins, G.; Brito de Souza, D.; Aguilar-Navarro, M.; Munoz-Guerra, J.; Plata, M.D.M.; Del Coso, J. Prevalence and patterns of dietary supplement use in elite Spanish athletes. J. Int. Soc. Sports Nutr. 2019, 16, 30. [CrossRef]
3. Australian Institute of Sport. ABCD Classification System. Australian Institute of Sport. 2017 [2018; 2018] Disponible en. Available online: https://ais.gov.au/nutrition/supplements#group_a (accessed on 18 April 2020).
4. Kerkcsick, C.M.; Wilborn, C.D.; Roberts, M.D.; Smith-Ryan, A.; Kleiner, S.M.; Jager, R.; Collins, R.; Cooke, M.; Davis, J.N.; Galvan, E.; et al. ISSN exercise & sports nutrition review update: Research & recommendations. J. Int. Soc. Sports Nutr. 2018, 15, 38. [PubMed]
5. Maughan, R.J.; Burke, L.M.; Dvorak, J.; Larson-Meyer, D.E.; Peeling, P.; Phillips, S.M.; Rawson, E.S.; Walsh, N.P.; Garthe, I.; Geyer, H.; et al. IOC consensus statement: Dietary supplements and the high-performance athlete. Br. J. Sports Med. 2018, 52, 439–455. [CrossRef] [PubMed]
6. Dominguez, R.; Cuenca, E.; Mate-Munoz, J.L.; Garcia-Fernandez, P.; Serra-Paya, N.; Estevan, M.C.L.; Herreros, P.V.; Garnacho-Castano, M.V. Effects of Beetroot Juice Supplementation on Cardiorespiratory Endurance in Athletes. A Systematic Review. Nutrients 2017, 9, 43. [CrossRef] [PubMed]
7. Poortmans, J.R.; Gualano, B.; Carpentier, A. Nitrate supplementation and human exercise performance: Too much of a good thing? Curr. Opin. Clin. Nutr. Metab. Care 2015, 18, 599–604. [CrossRef] [PubMed]
8. Wu, G.; Morris, S.M.J. Arginine metabolism: Nitric oxide and beyond. Biochem. J. 1998, 336, 1–17. [CrossRef]
9. Pahlavani, N.; Entezari, M.H.; Nasiri, M.; Miri, A.; Rezaie, M.; Bagheri-Bidakhavidi, M.; Sadeghi, O. The effect of L-arginine supplementation on body composition and performance in male athletes: A double-blinded randomized clinical trial. Eur. J. Clin. Nutr. 2017, 71, 544–548. [CrossRef]
10. Yavuz, H.U.; Turnagol, H.; Demirel, A.H. Pre-exercise arginine supplementation increases time to exhaustion in elite male wrestlers. Biol. Sport 2014, 31, 187–191. [CrossRef]
11. Hurst, H.; Hurst, H.T.; Sinclair, J.; Beenham, M. Influence of absolute versus relative L-arginine dosage on 1 km and 16.1 km time trial performance in trained cyclists. *J. Sci. Cycl.* 2014, 3, 2–8. [CrossRef] [PubMed]

12. Camic, C.L.; Housh, T.J.; Zuniga, J.M.; Hendrix, R.C.; Mielke, M.; Johnson, G.O.; Schmidt, R.J. Effects of arginine-based supplements on the physical working capacity at the fatigue threshold. *J. Strength Cond. Res.* 2010, 24, 1306–1312. [CrossRef] [PubMed]

13. Curtis, E.; Nicolis, I.; Moinard, C.; Osowska, S.; Zerrouk, N.; Benazeth, S.; Cynober, L. Almost all about citrulline in mammals. *Amino Acids* 2005, 29, 177–205. [CrossRef] [PubMed]

14. Morris, S.M. Arginine: Beyond protein. *Am. J. Clin. Nutr.* 2006, 83, 5085–512S. [CrossRef] [PubMed]

15. Huerta Ojeda, A.; Domínguez, A.; Barahona-Fuentes, G.D.F. Efecto de la suplementación de L-arginina y L-citrulina sobre el rendimiento físico: Una revisión sistemática. *Nutr. Hosp. Organ. La Soc. Esp. Nutr. Parenter. Y Enter.* 2019, 36, 389–1402.

16. Lundberg, J.O.; Weitzberg, E.; Gladwin, M.T. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. *Nat. Rev. Drug Discov.* 2008, 7, 156–167. [CrossRef]

17. Jones, A.M. Dietary nitrate supplementation and exercise performance. *Sports Med.* 2014, 44, S35–S45. [CrossRef]

18. Kanaley, J.A. Growth hormone, arginine and exercise. *Curr. Opin. Clin. Nutr. Metab. Care* 2008, 11, 50–54. [CrossRef]

19. Forbes, S.C.; Harber, V.; Bell, G.J. Oral L-arginine before resistance exercise blunts growth hormone in strength trained males. *Int. J. Sport Nutr. Exerc. Metab.* 2014, 24, 236–244. [CrossRef]

20. Campbell, B.; Roberts, M.; Kerksick, C.; Wilborn, C.; Marcello, B.; Taylor, L.; Nassar, E.; Leutholtz, B.; Bowden, R.; Rasmussen, C.; et al. Pharmacokinetics, safety, and effects on exercise performance of L-arginine alpha-ketoglutarate in trained adult men. *Nutrition* 2006, 22, 872–881. [CrossRef]

21. Borsheim, E.; Bui, Q.-U.T.; Tissier, S.; Kobayashi, H.; Ferrando, A.A.; Wolfe, R.R. Effect of amino acid supplementation on muscle mass, strength and physical function in elderly. *Clin. Nutr.* 2008, 27, 189–195. [CrossRef]

22. Fang, J.E.; Lysecki, P.J.; Manolakos, J.J.; McDonald, M.J.; Tarnopolsky, M.A.; Phillips, S.M. Bolus arginine supplementation affects neither muscle blood flow nor muscle protein synthesis in young men at rest or after resistance exercise. *J. Nutr.* 2011, 141, 195–200. [CrossRef] [PubMed]

23. Schaefer, A.; Piquard, F.; Geny, B.; Doutreleau, S.; Lampert, E.; Mettauer, B.; Lonsdorfer, J. L-arginine reduces exercise-induced increase in plasma lactate and ammonia. *Int. J. Sports Med.* 2002, 23, 403–407. [CrossRef] [PubMed]

24. Tsai, P.-H.; Tang, T.-K.; Juang, C.-L.; Chen, K.W.-C.; Chi, C.-A.; Hsu, M.-C. Effects of arginine supplementation on post-exercise metabolic responses. *Clin. J. Physiol.* 2009, 52, 136–142. [CrossRef] [PubMed]

25. Forbes, S.C.; Harber, V.; Bell, G.J. The acute effects of L-arginine on hormonal and metabolic responses during submaximal exercise in trained cyclists. *Int. J. Sport Nutr. Exerc. Metab.* 2013, 23, 369–377. [CrossRef]

26. Rowlands, D.S.; Clarke, J.; Green, J.G.; Shi, X. L-Arginine but not L-glutamine likely increases exogenous carbohydrate oxidation during endurance exercise. *Eur. J. Appl. Physiol.* 2012, 112, 2443–2453. [CrossRef]

27. Bassett, D.R.; Howley, E.T. Limiting factors for maximum oxygen uptake and determinants of endurance performance. *Med. Sci. Sports Exerc.* 2000, 32, 70–84. [CrossRef]

28. Joyner, M.J.; Coyle, E.F. Endurance exercise performance: The physiology of champions. *J. Physiol.* 2008, 586, 35–44. [CrossRef]

29. Jones, A.M.; Burnley, M. Oxygen uptake kinetics: An underappreciated determinant of exercise performance. *Int. J. Sports Physiol. Perform.* 2009, 4, 524–532. [CrossRef]

30. Bailey, S.J.; Winyard, P.G.; Vanhatalo, A.; Blackwell, J.R.; DiMenna, F.J.; Wilkerson, D.P.; Jones, A.M. Acute L-arginine supplementation reduces the O2 cost of moderate-intensity exercise and enhances high-intensity exercise tolerance. *J. Appl. Physiol.* 2010, 109, 1394–1403. [CrossRef]

31. Alvarenga, T.S.; Conte-Junior, C.A.; Silva, J.T.; Paschoalin, V.M.F. L-arginine does not improve biochemical and hormonal response in trained runners after 4 weeks of supplementation. *Nutr. Res.* 2014, 34, 31–39. [CrossRef]

32. Bailey, S.J.; Blackwell, J.R.; Lord, T.; Vanhatalo, A.; Winyard, P.G.; Jones, A.M. L-Citrulline supplementation improves O2 uptake kinetics and high-intensity exercise performance in humans. *J. Appl. Physiol.* 2015, 119, 385–395. [CrossRef] [PubMed]
33. Chamari, K.; Padulo, J. “Aerobic” and “Anaerobic” terms used in exercise physiology: A critical terminology reflection. *Sport. Med. Open* **2015**, *1*, 9. [CrossRef] [PubMed]

34. Gaitanos, G.C.; Williams, C.; Boobis, L.H.; Brooks, S. Human muscle metabolism during intermittent maximal exercise. *J. Appl. Physiol.* **1993**, *75*, 712–719. [CrossRef] [PubMed]

35. Gastin, P.B. Energy system interaction and relative contribution during maximal exercise. *Sports Med.* **2001**, *31*, 725–741. [CrossRef] [PubMed]

36. Sahlin, K. Muscle energetics during explosive activities and potential effects of nutrition and training. *Sports Med.* **2014**, *44*, S167–S173. [CrossRef]

37. Ghigo, E.; Arvat, E.; Valente, F.; Nicolosi, M.; Boffano, G.M.; Procopio, M.; Bellone, J.; Maccario, M.; Mazza, E.; Camanni, F. Arginine reinstates the somatotrope responsiveness to intermittent growth hormone-releasing hormone administration in normal adults. *Neuroendocrinology* **1991**, *54*, 291–294. [CrossRef]

38. Zajac, A.; Poprzecki, S.; Zebrowska, A.; Chalimoniuk, M.; Langfort, J. Arginine and ornithine supplementation increases growth hormone and insulin-like growth factor-I serum levels after heavy-resistance exercise in strength-trained athletes. *J. Strength Cond. Res.* **2010**, *24*, 1082–1090. [CrossRef]

39. Greer, B.K.; Jones, B.T. Acute arginine supplementation fails to improve muscle endurance or affect blood pressure responses to resistance training. *J. Strength Cond. Res.* **2011**, *25*, 1789–1794. [CrossRef]

40. Meirelles, C.M.; Matsuura, C. Acute supplementation of L-arginine affects neither strength performance nor nitric oxide production. *J. Sports Med. Phys. Fitness* **2018**, *58*, 216–220.

41. Mor, A.; Atan, T.; Ağaçğlu, S.A.; Ayyildiz, M. Effect of arginine supplementation on footballers’ anaerobic performance and recovery. *Prog. Nutr.* **2018**, *20*, 104–112.

42. Schneider, K.L.; Yahia, N. Effectiveness of Arginine Supplementation on Wound Healing in Older Adults in Acute and Chronic Settings: A Systematic Review. *Adv. Skin Wound Care* **2019**, *32*, 457–462. [CrossRef] [PubMed]

43. Rodrigues-Krause, J.; Krause, M.; Rocha, I.M.G.D.; Umpierre, D.; Fayh, A.P.T. Association of L-Arginine Supplementation with Markers of Endothelial Function in Patients with Cardiovascular or Metabolic Disorders: A Systematic Review and Meta-Analysis. *Nutrients* **2018**, *11*, 15. [CrossRef] [PubMed]

44. Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Ioannidis, J.P.A.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. *BMJ* **2009**, *339*, b2700. [CrossRef] [PubMed]

45. O’Connor, D.; Green, S.; Higgins, J.P. Defining the Review Question and Developing Criteria for Including Studies. In *Cochrane Handbook for Systematic Reviews of Interventions*; Cochrane Book Series; Cochrane: London, UK, 2008; pp. 81–94.

46. McHugh, M.L. Interrater reliability: The kappa statistic. *Biochem. Med.* **2012**, *22*, 276–282. [CrossRef]

47. Berthon, P.; Fellmann, N.; Bedu, M.; Beaune, B.; Dabonneville, M.; Coudert, J.; Chamoux, A. A 5-min running field test as a measurement of maximal aerobic velocity. *Eur. J. Appl. Physiol. Occup. Physiol.* **1997**, *75*, 233–238. [CrossRef]

48. Tong, T.K.; Fu, F.H.; Chow, B.C. Reliability of a 5-min running field test and its accuracy in VO2max evaluation. *J. Sports Med. Phys. Fit.* **2001**, *41*, 318–323.

49. Egger, M.; Davey Smith, G.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* **1997**, *315*, 629–634. [CrossRef]

50. Green, S.; Higgins, J. *Cochrane Handbook for Systematic Reviews of Interventions*; Version 5.0.2; Cochrane Libr: London, UK; Online Libr: Chichester, UK, 2009.

51. Hedges, L. V Distribution theory for Glass’s estimator of effect size and related estimators. *J. Educ. Stat.* **1981**, *6*, 107–128. [CrossRef]

52. DerSimonian, R.; Laird, N. Meta-analysis in clinical trials. *Control. Clin. Trials* **1986**, *7*, 177–188. [CrossRef]

53. Cohen, J. *Statistical Power Analysis for the Behavioral Sciences*; Academic Press: Cambridge, MA, USA, 2013; ISBN 1483276481.

54. Higgins, J.P.T.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. *BMJ* **2003**, *327*, 557–560. [CrossRef]

55. Borenstein, M.; Hedges, L.V.; Higgins, J.P.T.; Rothstein, H.R. *Introduction to Meta-Analysis*; John Wiley & Sons: Hoboken, NJ, USA, 2011; ISBN 1119964377.

56. Higgins, J.P.T.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. *Stat. Med.* **2002**, *21*, 1539–1558. [CrossRef] [PubMed]
57. Olek, R.A.; Ziemann, E.; Grzywacz, T.; Kujach, S.; Luszczyk, M.; Antosiewicz, J.; Laskowski, R. A single oral intake of arginine does not affect performance during repeated Wingate anaerobic test. *J. Sport. Med. Phys. Fit.* 2010, 50, 52–56.

58. Liu, T.H.; Wu, C.L.; Chiang, C.W.; Lo, Y.W.; Tseng, H.F.; Chang, C.K. No effect of short-term arginine supplementation on nitric oxide production, metabolism and performance in intermittent exercise in athletes. *J. Nutr. Biochem.* 2009, 20, 462–468. [CrossRef] [PubMed]

59. Álvares, T.S.; Conte, C.A.; Paschoalin, V.M.F.; Silva, J.T.; de Meirelles, C.M.; Bhambhani, Y.N.; Gomes, P.S.C. Acute L-arginine supplementation increases muscle blood volume but not strength performance. *Appl. Physiol. Nutr. Metab.* 2012, 37, 115–126.

60. Birol, A.; Kılınç, F.N.; Deliceoğlu, G.; Keskin, E.D. The effect of acute L-arginine supplementation on repeated sprint ability performance. *Prog. Nutr.* 2019, 21, 5–11.

61. Abel, T.; Knechtle, B.; Perret, C.; Eser, P.; Von Arx, P.; Knecht, H. Influence of chronic supplementation of arginine aspartate in endurance athletes on performance and substrate metabolism: A randomized, double-blind, placebo-controlled study. *Int. J. Sports Med.* 2005, 26, 344–349. [CrossRef]

62. Vanhatalo, A.; Bailey, S.J.; Dimenna, F.J.; Blackwell, J.R.; Wallis, G.A.; Jones, A.M. No effect of acute L-arginine supplementation on O2 cost or exercise tolerance. *Eur. J. Appl. Physiol.* 2013, 113, 1805–1819. [CrossRef]

63. Da Silva, D.V.T.; Conte, C.A.; Paschoalin, V.M.F.; Álvares, T.D.S. Hormonal response to L-arginine supplementation in physically active individuals. *Food Nutr. Res.* 2014, 58, 1–6.

64. Álvares, T.S.; Meirelles, C.M.; Bhambhani, Y.N.; Paschoalin, V.M.F.; Gomes, P.S.C. L-Arginine as a potential ergogenic aid in healthy subjects. *Sports Med.* 2011, 41, 233–248. [CrossRef]

65. Bonilla Ocampo, D.A.; Paipilla, A.F.; Marin, E.; Vargas-Molina, S.; Petro, J.L.; Perez-Idarraga, A. Dietary Nitrate from Beetroot Juice for Hypertension: A Systematic Review. *Biomolecules* 2018, 8, 134. [CrossRef] [PubMed]

66. Bode-Boger, S.M.; Boger, R.H.; Galland, A.; Tsikas, D.; Frolich, J.C. L-arginine-induced vasodilation in healthy humans: Pharmacokinetic-pharmacodynamic relationship. *Br. J. Clin. Pharmacol.* 1998, 46, 489–497. [CrossRef] [PubMed]

67. Burke, L.M.; Jeukendrup, A.E.; Jones, A.M.; Mooses, M. Contemporary Nutrition Strategies to Optimize Performance in Distance Runners and Race Walkers. *Int. J. Sport Nutr. Exerc. Metab.* 2019, 29, 117–129. [CrossRef] [PubMed]

68. Domínguez, R.; Maté-Muñoz, J.L.; Cuenca, E.; García-Fernández, P.; Mata-Ordoñez, F.; Lozano-Estevan, M.C.; Veiga-Herreros, P.; da Silva, S.F.; Garnacho-Castaño, M.V. Effects of beetroot juice supplementation on intermittent high-intensity exercise efforts. *J. Int. Soc. Sports Nutr.* 2018, 15, 2. [CrossRef] [PubMed]

69. Jones, A.M.; Ferguson, S.K.; Bailey, S.J.; Vanhatalo, A.; Poole, D.C. Fiber Type-Specific Effects of Dietary Nitrate. *Exerc. Sport Sci. Rev.* 2016, 44, 53–60. [CrossRef]

70. Vandelavalle, H.; Pérès, G.; Monod, H. Standard anaerobic exercise tests. *Sports Med.* 1987, 4, 268–289. [CrossRef]

71. Driss, T.; Vandelavalle, H. The measurement of maximal (anaerobic) power output on a cycle ergometer: A critical review. *Biomol. Res. Int.* 2013, 2013, 589361. [CrossRef]

72. Meckel, Y.; Machnai, O.; Eliakim, A. Relationship among repeated sprint tests, aerobic fitness, and anaerobic fitness in elite adolescent soccer players. *J. Strength Cond. Res.* 2009, 23, 163–169. [CrossRef]

73. San-Millan, I.; Brooks, G.A. Assessment of Metabolic Flexibility by Means of Measuring Blood Lactate, Fat, and Carbohydrate Oxidation Responses to Exercise in Professional Endurance Athletes and Less-Fit Individuals. *Sports Med.* 2018, 48, 467–479. [CrossRef]

74. Moran, C.N.; Pitsiladis, Y.P. Tour de France Champions born or made: Where do we take the genetics of performance? *J. Sports Sci.* 2017, 35, 1411–1419. [CrossRef]

75. Bescos, R.; Sureda, A.; Tur, J.A.; Pons, A. The effect of nitric-oxide-related supplements on human performance. *Sports Med.* 2012, 42, 99–117. [CrossRef]

76. Shea, B.J.; Reeves, B.C.; Wells, G.; Thuku, M.; Hamel, C.; Moran, J.; Moher, D.; Tugwell, P.; Welch, V.; Kristjansson, E.; et al. AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* 2017, 358, j4008. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).